MedinCell appointed Richard Malamut, MD as Chief Medical Officer. Before joining MedinCell as Chief Medical Officer, Dr. Richard Malamut was Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals and Chairman of MedinCell Medical Advisory Board. He also served as Chief Medical Officer for both Braeburn Pharmaceuticals and Avanir Pharmaceuticals.

Previously, from 2013 to 2016, he was the Senior Vice President of Global Clinical Development for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities at Teva Pharmaceuticals. Prior to that, he had multiple roles with increasing responsibilities at Bristol-Myers and AstraZeneca focused on early clinical development and translational medicine. Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in neuromuscular disease.

He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease.